UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors

Cancers, 2021-03, Vol.13 (5), p.1047

Yonesaka, Kimio

2021

Volltextzugriff (PDF)

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Clinical cancer research, 2018-06, Vol.24 (11), p.2653-2664

2018

Volltextzugriff (PDF)

HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy

Clinical colorectal cancer, 2017-12, Vol.16 (4), p.247-251

2017

Volltextzugriff (PDF)

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

International journal of cancer, 2019-12, Vol.145 (12), p.3414-3424

2019

Volltextzugriff (PDF)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

Cancer science, 2019-01, Vol.110 (1), p.52-60

2019

Volltextzugriff (PDF)

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Oncogene, 2019-02, Vol.38 (9), p.1398-1409

2019

Volltextzugriff (PDF)

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

British journal of cancer, 2021-03, Vol.124 (5), p.914-924

2021

Volltextzugriff (PDF)

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

Clinical cancer research, 2022-01, Vol.28 (2), p.390-403

2022

Volltextzugriff (PDF)

SY23-1 Antibody-drug conjugates (ADCs) in treatment-resistant cancers: From basic to clinical applications

Annals of oncology, 2023-11, Vol.34, p.S1370-S1370

Yonesaka, Kimio

2023

Volltextzugriff (PDF)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Cancer science, 2016-12, Vol.107 (12), p.1843-1850

2016

Volltextzugriff (PDF)

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Science translational medicine, 2011-09, Vol.3 (99), p.99ra86

2011

Volltextzugriff (PDF)

HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy

Recent patents on anti-cancer drug discovery, 2016-08, Vol.11 (3), p.267

2016

Volltextzugriff (PDF)

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

International journal of clinical oncology, 2021-09, Vol.26 (9), p.1628-1639

2021

Volltextzugriff (PDF)

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.71-82

2022

Volltextzugriff (PDF)

Sorafenib Inhibits Non―Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells

Cancer research (Chicago, Ill.), 2009-08, Vol.69 (16), p.6515-6521

2009

Volltextzugriff (PDF)

Impact of coexisting gene mutations in EGFR-mutated non–small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.28-34

2020

Volltextzugriff (PDF)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

Cancer medicine (Malden, MA), 2019-03, Vol.8 (3), p.1258-1268

2019

Volltextzugriff (PDF)

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer

Molecular cancer therapeutics, 2017-11, Vol.16 (11), p.2563-2571

2017

Volltextzugriff (PDF)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

Oncotarget, 2014-12, Vol.5 (23), p.11847-11856

2014

Volltextzugriff (PDF)

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

Scientific reports, 2019-08, Vol.9 (1), p.11340-8, Article 11340

2019

Volltextzugriff (PDF)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Oncotarget, 2015-10, Vol.6 (32), p.33602-33611

2015

Volltextzugriff (PDF)

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

Clinical cancer research, 2008-11, Vol.14 (21), p.6963-6973

2008

Volltextzugriff (PDF)

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018, Vol.21 (1), p.84-95

2018

Volltextzugriff (PDF)

Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

Esophagus : official journal of the Japan Esophageal Society, 2023-04, Vol.20 (2), p.281-289

2023

Volltextzugriff (PDF)

Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report

Thoracic cancer, 2023-01, Vol.14 (2), p.214-217

2023

Volltextzugriff (PDF)

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(95)
Berichte
(4)

Sprache

Englisch
(96)
Japanisch
(23)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(52)
Oncology
(49)
Humans
(46)
Female
(23)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(21)
Lung Neoplasms - Drug Therapy
(20)
Tumors
(20)
Lung Cancer
(18)
Male
(18)
Mutation
(18)
Aged
(17)
Cell Line, Tumor
(15)
Middle Aged
(15)
Carcinoma, Non-Small-Cell Lung - Pathology
(14)
Epidermal Growth Factor
(14)
Lung Neoplasms - Pathology
(14)
Animals
(12)
Carcinoma, Non-Small-Cell Lung - Genetics
(12)
Chemotherapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer

SY23-1 Antibody-drug conjugates (ADCs) in treatment-resistant cancers: From basic to clinical applications

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M–positive lung cancer after osimertinib

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis

Sorafenib Inhibits Non―Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells

Impact of coexisting gene mutations in EGFR-mutated non–small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)

Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report

Suchergebnisse filtern